Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Xencor Inc

Healthcare US XNCR

11.79USD
0.37(3.24%)

Last update at 2026-06-04T17:46:00Z

Day Range

11.5112.10
LowHigh

52 Week Range

16.4927.70
LowHigh

Fundamentals

  • Previous Close 11.42
  • Market Cap1442.90M
  • Volume461471
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-122.19500M
  • Revenue TTM162.18M
  • Revenue Per Share TTM2.67
  • Gross Profit TTM -34.98400M
  • Diluted EPS TTM-2.17

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -54.50800M 82.63M -69.33300M 27.19M -70.40900M
Minority interest - - - - -
Net income -55.18100M 82.63M -63.53900M 26.88M -70.40900M
Selling general administrative 47.49M 38.84M 29.69M 24.29M 22.47M
Selling and marketing expenses - - - - -
Gross profit 164.58M 275.11M 122.69M 156.70M 40.60M
Reconciled depreciation 8.80M 7.49M 5.79M 4.30M 3.25M
Ebit -91.27200M 36.28M -82.59100M 9.53M -82.62100M
Ebitda -82.47300M 43.77M -76.79700M 13.82M -79.37000M
Depreciation and amortization 8.80M 7.49M 5.79M 4.30M 3.25M
Non operating income net other - 36.43M -0.88700M 1.88M 9.81M
Operating income -82.47300M 43.77M -76.79700M 9.53M -79.37000M
Other operating expenses 247.05M 231.34M 199.49M 142.88M 119.97M
Interest expense -36.76400M 7.49M 0.00000M 17.66M 0.02M
Tax provision 0.67M 0.00000M 0.00000M 0.31M 0.00000M
Interest income 4.82M 0.85M 7.26M 13.62M 9.10M
Net interest income 4.82M 0.85M 7.26M 13.62M 9.09M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.67M -7.49100M -5.79400M 0.31M 8.98M
Total revenue 164.58M 275.11M 122.69M 156.70M 40.60M
Total operating expenses 247.05M 231.34M 199.49M 142.88M 119.97M
Cost of revenue - - - 118.59M 97.50M
Total other income expense net 27.96M 38.86M 7.46M 17.66M 8.96M
Discontinued operations - - - - -
Net income from continuing ops -55.18100M 82.63M -69.33300M 26.88M -70.40900M
Net income applicable to common shares -55.18100M 82.63M -69.33300M 26.88M -70.40900M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 952.69M 846.27M 838.21M 703.24M 670.25M
Intangible assets 18.66M 18.50M 16.49M 15.98M 14.42M
Earning assets - - - - -
Other current assets 18.14M 23.28M 60.74M 10.73M 6.55M
Total liab 283.56M 118.77M 104.71M 130.80M 77.05M
Total stockholder equity 668.80M 727.50M 733.50M 572.44M 593.20M
Deferred long term liab - - - - -
Other current liab 29.35M 18.73M 19.44M 17.60M 8.99M
Common stock 0.61M 0.60M 0.59M 0.58M 0.57M
Capital stock 0.61M 0.60M 0.59M 0.58M 0.57M
Retained earnings -464.37200M -338.28500M -283.10400M -365.73500M -296.40200M
Other liab - - - - 1.93M
Good will - - - - -
Other assets - 0.61M 5.65M 0.21M 0.71M
Cash 53.79M 53.94M 143.48M 163.54M 50.31M
Cash and equivalents - - - - -
Total current liabilities 84.71M 63.84M 70.74M 121.06M 66.56M
Current deferred revenue 31.68M 30.32M 37.29M 92.61M 45.20M
Net debt 29.64M 5.69M -109.51100M -151.91600M -39.57800M
Short term debt 9.77M 4.71M 33.97M 1.89M 2.17M
Short long term debt 6.33M - - - -
Short long term debt total 83.43M 59.63M 33.97M 11.63M 10.73M
Other stockholder equity 1130.93M 1072.13M 1017.52M 937.52M 887.87M
Property plant equipment - 93.60M 59.97M 21.68M 15.80M
Total current assets 623.16M 675.34M 424.37M 637.67M 558.40M
Long term investments 209.72M 58.21M 331.73M 17.10M 71.93M
Net tangible assets - 709.00M 717.01M 556.47M 578.78M
Short term investments 539.93M 569.12M 190.63M 439.46M 479.47M
Net receivables 11.29M 29.00M 66.38M 23.94M 22.08M
Long term debt 14.64M - - - -
Inventory -11.29000M - -36.86000M - -
Accounts payable 13.91M 10.09M 14.00M 8.95M 10.19M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.29M -6.95200M -1.51000M 0.07M 1.16M
Additional paid in capital - - - - -
Common stock total equity - - 0.59M 0.58M 0.57M
Preferred stock total equity - - - - -
Retained earnings total equity - - -283.10400M -365.73500M -296.40200M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 119.43M 0.61M 0.65M 0.21M 0.31M
Deferred long term asset charges - - - - -
Non current assets total 329.53M 170.92M 413.84M 65.57M 111.84M
Capital lease obligations 62.46M 59.63M 33.97M 11.63M 10.73M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -119.72500M -29.44500M 113.96M -39.93200M -155.62900M
Change to liabilities -10.88700M 6.89M 7.37M 5.72M 0.95M
Total cashflows from investing activities -119.72500M -46.24900M 100.19M -50.97000M -164.76700M
Net borrowings - - - - -
Total cash from financing activities 5.70M 43.04M 18.04M 10.66M 254.24M
Change to operating activities 22.36M -9.44500M 5.30M 2.62M -0.77000M
Net income -55.18100M 82.63M -69.33300M 26.88M -70.40900M
Change in cash -89.53800M -20.06400M 113.23M 24.07M 9.72M
Begin period cash flow 143.48M 163.54M 50.31M 26.25M 16.53M
End period cash flow 53.94M 143.48M 163.54M 50.31M 26.25M
Total cash from operating activities 24.48M -16.85300M -5.00400M 64.37M -79.75600M
Issuance of capital stock 0.00000M 28.92M 0.00000M 0.00000M 260.25M
Depreciation 8.80M 7.49M 5.79M 4.30M 3.25M
Other cashflows from investing activities 5.00M -3.50500M -3.22800M -3.68500M -1.92600M
Dividends paid - - - - -
Change to inventory - 1.40M -5.87800M 3.48M -1.36300M
Change to account receivables 37.39M -54.94100M 10.13M -11.32100M -9.04500M
Sale purchase of stock 2.09M 1.84M 1.43M 1.39M 0.94M
Other cashflows from financing activities -119.72500M 12.28M 16.62M 9.27M -6.94000M
Change to netincome 22.00M 39.13M 5.34M 32.08M 20.96M
Capital expenditures 43.40M 15.98M 13.77M 11.04M 9.15M
Change receivables - -54.28600M 11.32M -11.70800M -9.58000M
Cash flows other operating - -101.86900M 34.77M 11.43M -24.54000M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -20.06400M 113.23M 24.07M 9.72M
Change in working capital 48.87M -102.60100M 48.18M 5.44M -33.16700M
Stock based compensation 48.91M 36.98M 31.62M 31.85M 20.55M
Other non cash items -26.91100M -22.37900M -21.27000M -4.09200M 0.02M
Free cash flow -18.91900M -32.83400M -18.77200M 53.34M -88.90300M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
XNCR
Xencor Inc		 0.37 3.24% 11.79 - - 7.44 1.87 4.40 -5.8317
NVO
Novo Nordisk A/S		 1.81 4.32% 43.81 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.23% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 12.68 2.96% 441.01 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.44 1.04% 625.39 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104, which is in Phase II clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase Ia clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; XmAb541 for the treatment of ovarian cancer; and XmAb662 which is in Phase I clinical trial to treat patients with solid tumors. In addition, the company develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; and VIR-2482 that is in Phase 2 clinical trial to trat hepatitis B virus. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Pasadena, California.

Xencor Inc

465 North Halstead Street, Pasadena, CA, United States, 91107

Key Executives

Name Title Year Born
Dr. Bassil I. Dahiyat Ph.D. Co-Founder, CEO, Pres & Director 1970
Mr. John J. Kuch Sr. VP & CFO 1959
Dr. John R. Desjarlais Sr. VP of Research & Chief Scientific Officer 1964
Ms. Celia E. Eckert J.D. Sr. VP, Gen. Counsel & Corp. Sec. 1973
Dr. Allen S. Yang M.D., Ph.D. Sr. VP & Chief Medical Officer 1968
Mr. Charles Liles Associate Director and Head of Corp. Communications & Investor Relations NA
Ms. Jennifer Sandoz VP of HR NA
Dr. Jeremy Grunstein Ph.D. Sr. VP of Bus. Devel. NA
Mr. Kirk Rosemark RAC Sr. VP of Regulatory Affairs & Quality Assurance 1965
Dr. Bassil I. Dahiyat Ph.D. Co-Founder, CEO, President & Director 1970

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.